Metastatic lung cancer patient finds effective therapy in clinical trial

Treatment Terms Lung cancer Additional SEO Keywords lung cancer, metastatic cancer, metastatic lung cancer, brain metastases, clinical trial, cancer clinical trial, experimental cancer medication, experimental cancer therapy SEO Meta Description Ginger Scott needed new options to treat her metastatic lung cancer. A clinical trial at Duke gave her just that. Author MaryAnn Fletcher Overview Ginger Scott needed new options to treat her metastatic lung cancer. A clinical trial at Duke gave her just that. Hero Image 20160706.scott_.ginger.blog_.01.jpg Preview Image Content Blocks Content Scott, a healthy, athletic 40-year-old mom of three, was in her Whiteville, NC, home, preparing food for a holiday party when she began to feel dizzy. “I thought, ‘Oh, I must need something to drink’ and took a break,” said Scott. “Within 20 seconds, I went into a full grand-mal seizure.” A series of scans revealed the cause of her seizure: tumors in her brain that had spread from her lung. A biopsy confirmed that Scott, who had never smoked, had non-small cell lung cancer. Almost immediately, she began receiving radiation treatment. She also began taking an oral medication targeted to her type of cancer. Scott’s cancer cells had an EGFR mutation, meaning they had an overactive form of a protein called epidermal growth factor receptor (EGFR) on their surface, wh...
Source: Duke Health News - Category: Consumer Health News Authors: Source Type: news

Related Links:

Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). D...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Publication date: November 2018Source: Pharmacological Research, Volume 137Author(s): Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Maria C. Lebre, Jos H. Beijnen, Alfred H. SchinkelAbstractBrigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC). Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, and the multispecific drug-metabolizing enzyme CYP3 A in plasma pharmacokinetics and tissue distribution of brigatinib. In vitro, brigatinib was exceptionally well transpo...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Conclusions: Exact incidence of T790M mutations after progression on TKI s in Asian population is not exactly known and requires large data, as incidence may be different than reported in the Western population. Rebiopsy and ddPCR help to determine the most common type of resistance after progression on TKI, for which effective targeted therapy is available.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Authors: Alshangiti A, Chandhoke G, Ellis PM Abstract Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor pe...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
AbstractThe identification of anaplastic lymphoma kinase rearrangements in 2 –5% of patients with non-small-cell lung cancer led to rapid advances in the clinical development of oral tyrosine kinase inhibitors. Anaplastic lymphoma kinase inhibitors are an effective treatment in preclinical models and patients with anaplastic lymphoma kinase-translocated cancers. Four anapl astic lymphoma kinase inhibitors (crizotinib, ceritinib, alectinib, and brigatinib) have recently been approved. Post-marketing studies provided additional pharmacokinetic information on their pharmacokinetic parameters. The pharmacokinetic propert...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
Conclusions: In BM and non-BM EGFR+ patients, late stage of disease at presentation, as well as TKI in second line, may contribute to the similar clinical outcome.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
ConclusionsApatinib is effective and well tolerated in patients with advanced NSCLC, even at a dosage of 500 mg qd, and might offer a new option for the treatment of such patients with brain metastases.
Source: Asia-Pacific Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionNivolumab and concomitant high-dose corticosteroid therapy was found to be efficient and well tolerated.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
This study provides evidence that some patients [with mesothelioma] can have long-term disease control with this drug, which we haven’t seen before,” Alley said in a press release. “This drug appears to be well tolerated.” Real Need for Second-Line Therapy Standard first-line therapy for mesothelioma includes a combination of chemotherapy, radiation and surgery, but it remains relatively ineffective as a long-term solution. Alley believes pembrolizumab, classified as a checkpoint inhibitor drug, can provide a needed advancement in treatment. Checkpoint inhibitors allow the immune system to fight off...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center checkpoint inhibitors Dr. Evan Alley keytruda keytruda clinical trials keytruda for mesothelioma Merck & Co. PD-L1 proteins pembrolizumab Pembrolizumab mesothelioma Penn Medicine Penn Presbyterian Medical Cente Source Type: news
ConclusionsThis study demonstrates the clinical activity and manageable tolerability of ceritinib in a Japanese subset of chemotherapy- and crizotinib-pretreated patients withALK-rearranged non-small cell lung cancer who progressed on crizotinib, as was shown in the whole ASCEND-2 study identifier: NCT01685060
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Blogging | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Ginger | Health | Learning | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Oral Cancer | PET Scan | Smokers | Universities & Medical Training